Multiomics analysis couples mRNA turnover and translational control of glutamine metabolism to the differentiation of the activated CD4 + T cell.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro multiomics mechanistic study with no human clinical trial data.
PubMed 36385275 · doi:10.1038/s41598-022-24132-6
What was done
Researchers evaluated the post-transcriptional metabolic regulation of CD4+ T cells lacking the RNA-binding proteins Zfp36 and Zfp36l1. The study combined measurements of mRNA transcription, stability, abundance, and translation with crosslinking immunoprecipitation and metabolic profiling to determine how ZFP36 and ZFP36L1 regulate T cell metabolism and differentiation.
What was found
The abstract reports no numerical values, effect sizes, or statistical metrics. Qualitatively, ZFP36 and ZFP36L1 directly bound and repressed transcripts for transcription factors and rate-limiting enzymes across glycolysis, one-carbon metabolism, and glutaminolysis. ZFP36/ZFP36L1 deficiency led to increased cellular glutamine content, correlating with direct binding to the glutamine transporter SLC38A2 transcript, and increased conversion of glutamine to alpha-ketoglutarate, consistent with binding to Gls and Glud1 transcripts. These mechanisms restrained glutamine anaplerosis and the acquisition of the cytotoxic CD4+ T cell fate.
Why it matters
The study identifies ZFP36 and ZFP36L1 as direct post-transcriptional regulators of metabolic reprogramming, showing they constrain glutamine transport and catabolism to regulate activated CD4+ T cell differentiation.
Limits
This is bench-level preclinical mechanistic research. The abstract does not report numerical data, exact sample size or replicates, donor organism source, or in vivo functional disease outcomes.
Cited by
- supports Activated T cells consume glutamine and convert it to alpha-ketoglutarate as an energy source.